By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Zelos Therapeutics 

Waltham  Massachusetts    U.S.A.
Phone: n/a Fax:




Company News
Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatide 1/28/2010 8:30:18 AM
Zelos Therapeutics Initiates Clinical Study of First US Injectable Equivalent to Forteo(R) (teriparatide) 10/7/2009 7:59:41 AM
Zelos Therapeutics to Present at Two Investor Conferences 10/23/2008 12:17:18 PM
Zelos Therapeutics Reaches Agreement with the FDA and EMEA for a Registration Study of ZT-031 for the Treatment of Osteoporosis 7/24/2008 7:19:26 AM
Zelos Therapeutics Appoints Alan S. Roemer as Chief Financial Officer 6/17/2008 8:55:22 AM
Zelos Therapeutics and Aegis Therapeutics, LLC Announce Collaboration for Intranasal Delivery of Zelos' ZT-031 4/16/2008 6:54:46 AM
Zelos Therapeutics Appoints David S. Krause, MD, FACP, as Chief Medical Officer 3/20/2008 8:49:53 AM
Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C(TM)) 9/19/2007 10:47:40 AM
Zelos Therapeutics' Ostabolin-C(TM) Increases Bone Mineral Density In Phase 2 Osteoporosis Trial 2/8/2007 11:52:40 AM
The Day In Review: Big M&A Activity In Biotech 9/21/2006 6:43:54 PM